Subcutaneous infusions of apomorphine: A reappraisal of its therapeutic efficacy in advanced Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 13, Issue 12, 2013, Pages 1343-1353

  Grandas, Francisco ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

apomorphine; dyskinesias; levodopa induced motor complications; motor fluctuations; Parkinson's disease; subcutaneous infusion

Indexed keywords

APO GO; APOMORPHINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOMPERIDONE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; POSTSYNAPTIC RECEPTOR; UNCLASSIFIED DRUG;

ABSCESS; ANHEDONIA; ANXIETY; ATTENTION DEFICIT DISORDER; AUTOIMMUNE HEMOLYTIC ANEMIA; BRAIN DEPTH STIMULATION; CLINICAL TRIAL (TOPIC); COGNITION; COMPARATIVE STUDY; CONFUSION; CONTINUOUS INFUSION; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; DROWSINESS; DRUG EFFICACY; DYSKINESIA; EOSINOPHILIA; FATIGUE; FOLLOW UP; HALLUCINATION; HICCUP; HUMAN; HYPERHIDROSIS; HYPERSEXUALITY; INJECTION SITE CONTUSION; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INSOMNIA; MANIA; MINI MENTAL STATE EXAMINATION; MOOD; MOTIVATION; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROSIS; NOCTURIA; ORTHOSTATIC HYPOTENSION; PANNICULITIS; PARANOIA; PARKINSON DISEASE; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SALIVA; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SKIN ULCER; SOMNOLENCE; URINARY DYSFUNCTION; VISUAL HALLUCINATION; VOMITING;

ANIMALS; APOMORPHINE; DOPAMINE AGONISTS; HUMANS; INFUSIONS, SUBCUTANEOUS; PARKINSON DISEASE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84887941096     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.839235     Document Type: Review

References (80)

1. Obeso JA, Grandas F, Vaamonde J et al. Motor complications associated with chronic levodopa therapy in parkinson's disease. Neurology 39(39Suppl. 2), 11-19 (1989
2. Ahlskog J. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3), 448-458 (2001
3. Mattheissen A. Research into the chemical constitution of the opium bases. Part 1: On the action of hydrochloric acid on morphia. Proc. R. Soc. Lond. B. Biol. Sc. 17, 455-460 (1869
4. Neumeyer LS, Baldessarini RJ. Historical highlights of the chemistry, pharmacology, and early clinical uses of apomorphine. In: Apomorphine and Other Dopaminomimetics. Volume 1. Basic Pharmacology. Gessa GL, Corsini GU (Eds). Raven Press, NY, USA, 1-17 (1981
5. Schwab R, Lettvin J. Apomorphine in parkinson's disease. Trans. Am. Neurol. Assoc. 76, 251-253 (1951
6. Cotzias GC, Papavisiliou PS, Fheling C, Kaufman B, Mena I. Similarities between neurologic effects of L-dopa and apomorphine. N.Engl. J. Med. 282, 31-33 (1970
7. Duby SE, Cotzias CG, Papavasiliou PS, Lawerence WH. Injected apomorphine and orally administered levodopa in parkinsonism. Arch. Neurol. 27, 474-480 (1972
8. Corsini G, Del Zompo M, Gessa G, Mangoni A Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in parkinson's disease. Lancet (1), 954-956 (1979
9. Hutchinson LR, Dostrovsky J, Lozano A, Lang A. Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann. Neurol. 42(5), 767-775 (1997
10. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin J, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profi les of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 303, 791-804 (2002
11. Nutt J, Woodward W Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 38, 1553-1557 (1988
12. Newman-Tacredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of Dopamine D2-like receptors and a 1/ a 2-adrenoceptor. J. Pharmacol. Exp. Ther. 303, 805-814 (2002
13. Deleu D, Northway M Subcutaneous apomorphine: An evidence-based review of its use in parkinson's disease. Drugs Aging. 21(11), 687-709 (2004
14. Manson AJ, Hanagasi H, Turner K et al Intravenous apomorphine therapy in parkinson's disease: Clinical and pharmacokinetic observations. Brain 124 (Part 2), 331-340 (2001
15. Ondo W, Hunter C, Almaguer M, Gancher S, Jankovic J. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fl uctuating parkinson's disease. Clin. Neuropharmacol. 22 (1), 1-4 (1999
16. Van Laar T, Neef C, Danhof M, Roos R. Pharmacokinetics and clinical effi cacy of rectal apomorphine in patients with parkinson's disease: A study of five different suppositories. Mov. Disord. 10 (4), 433-439 (1995
17. Kapoor R, Turjanski N, Frankel J et al. Intranasal apomorphine: A new treatment in parkinson's disease. J. Neurol. Neurosurg. Psychiatry 53 (11), 1015 (1990
18. Priano L, Albani G, Brioschi A et al. Transdermal apomorphine permeation from microemulsions: A new treatment in parkinson's disease. Mov. Disord. 19(8), 937-942 (2004
19. Chase TN, Metman VL, Bravi D, Roberts JV, Sibley DR, Mouradian Ml. Dopamine-receptor subtype-selective agonists in the treatment of Parkinsońs disease. Clin. Neuropharmacol. 18(Suppl. 18), S207-S215 (1995
20. Kempster, Stern G, Lees AJ. Comparison of motor response to apomorphine and levodopa in parkinsońs disease. J. Neurol. Neurosurg. Psychiatry 53(11), 1004-1007 (1990
21. Merello M, Cammarota A, Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible madopar latence and effect duration in parkinson's disease patients: A double blind single-dose study. Clin. Neuropharmacol. 20(2), 165-167 (1997
22. Gancher S, Boucher B, Nutt J. Peripheral pharmacokinetics of apomorphine in humans. Ann. Neurol. 26(2), 232-238 (1989
23. Gancher ST, Woodward WR, Gliessman P, Boucher B, Nutt JG. The short-duration response to apomorphine: Implications for the mechanism of dopaminergic effects in parkinsonism. Ann. Neurol. 27(6), 660-665 (1990
24. Gancher S. Pharmacokinetics of apomorphine in parkinson's disease. J. Neural Transm.Suppl. 45, 137-141 (1995
25. Van Der Geest R, Van Laar LT, Kruger PP et al. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin. Neuropharmacol. 21, 159-168 (1998
26. Van Der Geest R, Kruger P, Gubbens-Stibbe JM, Van Laar T, Bodde HE, Danhof M. Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with parkinson's disease. J. Chromatogr. B. Biomed. Sci. Appl. 702, 131-141 (1997
27. Gassen M, Pinchasi B, Youdim M. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308(2), 219-225 (1996
28. Gassen M, Youdim M. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov. Disord. 13(2), 242-248 (1998
29. Grünblatt E, Berkuzki T, Youdim M. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14(4), 612-618 (1999
30. Grünblatt E, Maor G, Youdim M. Effects of R-and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem. 77(1), 146-156 (2001
31. Fornai F, Battaglia G, Gesi M, Orzi F, Nicoletti F, Ruggieri S Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res. 898(1), 27-35 (2001
32. Ohta M, Ohta K, Nishimura M, Mizuta E, Hayashi K, Kuno S. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 272(1), 18-22 (2000
33. Yuan H, Ebinger G, Michotte Y Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of parkinson's disease. Brain Res. 1026(1), 95-107 (2004
34. Battaglia G, Cuomo L, Giorgi F et al Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice. Neuropharmacology 42(3), 367-373 (2002
35. Kyriazis M. Neuroprotective, anti-apoptotic effects of apomorphine. J. Anti. Aging. Med. 6(1), 21-28 (2003
36. The National Collaborating Centre for Chronic Conditions FTPGFTNBN. Parkison's Disease. National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. Royal College of Physicians, London, UK (2006
37. Stibe C, Lees A, Stern G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet 1(8537), 871 (1987
38. Obeso JA, Grandas F, Vaamonde J, Luguin RM, Martinez-Lage JM Apomorphine infusion for motor fluctuations in parkinson's disease. Lancet 1(8546), 1376-1377 (1987
39. Chaudhuri KR, Critchley P, Abbott RJ, Pye IF, Millac PA. Subcutaneous apomorphine for on-off oscillations in parkinson's disease. Lancet 2(8622), 1260 (1988
40. Stibe CM, Lees AJ, Kempster PA, Stern GM Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1(8582), 403-406 (1988
41. Hughes AJ, Bishop S, Kleedorfer B et al. Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years. Mov. Disord. 8(2), 165-170 (1993
42. Pollak P, Champay AS, Hommel M, Perret JE, Benabid AL. Subcutaneous apomorphine in parkinson's disease. J. Neurol. Neurosurg. Psychiatry 52(4), 544 (1989
43. Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J. [Subcutaneous administration of apomorphine in motor fluctuations in parkinson's disease]. Rev. Neurol. (Paris) 146(2), 116-122 (1990
44. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in parkinson's disease. J. Neurol. Neurosurg. Psychiatry 64(5), 573-576 (1998
45. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of parkinson's disease. J. Neurol. Neurosurg. Psychiatry 53(2), 96-101 (1990
46. Kreczy-Kleedorfer B, Wagner M, Bosch S, Poewe W Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease. Nervenarzt 64(4), 221-225 (1993
47. Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating parkinson's disease. Long-term follow-up in 18 patients. Adv. Neurol. 60, 656-659 (1993
48. Stocchi F, Bramante L, Monge A et al. Apomorphine and lisuride infusion. A comparative chronic study. Adv. Neurol. 60, 653-655 (1993
49. Wenning GK, Bosch S, Luginger E, Wagner M, Poewe W. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv. Neurol. 80, 545-548 (1999
50. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in parkinson's disease: Clinical utility and lack of tolerance. Mov. Disord. 10(1), 37-43 (1995
51. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: A long term follow up. J. Neurol. Neurosurg. Psychiatry 65(5), 709-716 (1998
52. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with parkinson's disease: Long-term results. Neurol. Sci. 22(1), 93-94 (2001
53. Kanovsky P, Kubova D, Bares M et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up. Mov. Disord. 17(1), 188-191 (2002
54. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of parkinson's disease: Long-term follow-up study of 64 patients. Mov. Disord. 17(6), 1235-1241 (2002
55. Morgante L, Basile G, Epifanio A et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: A follow-up of two years. Arch. Gerontol. Geriatr.Suppl. (9), 291-296 (2004
56. Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ. A 10 year retrospective audit of long-term apomorphine use in parkinson's disease. J. Neurol. 251(11), 1370-1374 (2004
57. Katzenschlager R, Hughes A, Evans A et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in parkinson's disease: A prospective study using single-dose challenges. Mov. Disord. 20(2), 151-157 (2005
58. Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study. Mov. Disord. 23(8), 1130-1136 (2008
59. Drapier S, Gillioz AS, Leray E et al. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. Parkinsonism Relat. Disord. 18(1), 40-44 (2012
60. Martinez-Martin PP R, Antonini A, Henriken T et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: A real life study of non motor effect. J. Parkinsons Dis. 1, 197-203 (2011
61. Alegret M, Valldeoriola F, Marti M et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in parkinson's disease. Mov. Disord. 19(12), 1463-1469 (2004
62. De Gaspari D, Siri C, Landi A et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry 77(4), 450-453 (2006
63. Antonini A, Isaias IU, Rodolfi G et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J. Neurol. 258(4), 579-585 (2011
64. Grandas F, Gancher ST, Rodriguez M, Lera G, Nutt JG, Obeso JA. Differences in the motor response to apomorphine between untreated and fluctuating patients with parkinson's disease. Clin. Neuropharmacol. 15(1), 13-18 (1992
65. Grandas F, Gancher S, Lera G et al Time interval between repeated injections conditions the duration of motor improvement to apomorphine in parkinson's disease. Neurology 42(7), 1287-1290 (1992
66. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model. Mov. Disord. 20(2), 130-140 (2005
67. Ellis C, Lemmens G, Parkes JD et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism. Relat. Disord. 3(2), 103-107 (1997
68. Van Laar T, Postma AG, Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with parkinson's disease and pre-existing visual hallucinations. Parkinsonism. Relat. Disord. 16(1), 71-72 (2010
69. Geerligs L, Meppelink AM, Brouwer WH, Van Laar T. The effects of apomorphine on visual perception in patients with parkinson disease and visual hallucinations: A pilot study. Clin. Neuropharmacol. 32(5), 266-268 (2009
70. Grandas F, Iranzo A. Nocturnal problems occurring in parkinson's disease. Neurology 63(63Suppl. 3), S8-11 (2004
71. Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in parkinson's disease and restless legs syndrome. Acta. Neurol. Scand. 100(3), 163-167 (1999
72. Garcia Ruiz PJ. Nocturnal subcutaneous apomorphine infusion for severe insomnia in parkinson's disease. Mov. Disord. 21(5), 727-728 (2006
73. Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with parkinson's disease with symptom fluctuations. Acta. Neurol. Scand. 119(5), 345-348 (2009
74. Reddy P, Odin P, Antonini A et al. A multicenter European comparative survey of motor and non motor effects of subcutaneous apomorphine infusion and intrajejunal levodopa infusion in parkinson's disease. Mov. Disord. 27(Suppl. 27), 106 (2012
75. Conditions NCCFC. Parkinson's disease. National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. Royal College of Physicians, London, UK (2006
76. Gui'a oficial de pra'ctica cli'nica en la enfermedad de Parkinson. Neurologi'a GODLSED. Ruiz-Espiga PJG, Castrillo JCM (Ed.). Thomson Reuters, Madrid, Spain (2009
77. Hagell P, Odin P. Apomorphine in the treatment of parkinson's disease. J. Neurosci. Nurs. 33(1), 21-34, 37-28 (2001
78. Castano B, Mateo D, Gimenez-Roldan S Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: Experience and recommendations. Neurologia 22(3), 133-137 (2007
79. Di Rosa AE, Epifanio A, Antonini A et al. Continuous apomorphine infusion and neuropsychiatric disorders: A controlled study in patients with advanced Parkinson's disease. Neurol. Sci. 24(3), 174-175 (2003
80. Valldeoriola F, Puig-Junoy J, Puig-Peiro R. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study. J. Med. Econ. 16(2), 191-201 (2012